DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Daseuli | ko |
dc.contributor.author | Han, Hee-Jeong | ko |
dc.contributor.author | Yu, Jeonghye | ko |
dc.contributor.author | Kim, Jihye | ko |
dc.contributor.author | Lee, Gun-Hee | ko |
dc.contributor.author | Yang, Ju-Hee | ko |
dc.contributor.author | Song, Byeong-Min | ko |
dc.contributor.author | Tark, Dongseob | ko |
dc.contributor.author | Choi, Byeong-Sun | ko |
dc.contributor.author | Kang, Sang -Min | ko |
dc.contributor.author | Do Heo, Won | ko |
dc.date.accessioned | 2023-07-18T01:01:36Z | - |
dc.date.available | 2023-07-18T01:01:36Z | - |
dc.date.created | 2023-07-17 | - |
dc.date.created | 2023-07-17 | - |
dc.date.created | 2023-07-17 | - |
dc.date.created | 2023-07-17 | - |
dc.date.issued | 2023-06 | - |
dc.identifier.citation | MOLECULAR THERAPY, v.31, no.6, pp.1675 - 1687 | - |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.uri | http://hdl.handle.net/10203/310549 | - |
dc.description.abstract | CRISPR-Cas13-mediated viral genome targeting is a novel strategy for defending against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Here, we generated mRNA-encoded Cas13b targeting the open reading frame 1b (ORF1b) region to effectively degrade the RNA-dependent RNA polymerase gene. Of the 12 designed CRISPR RNAs (crRNAs), those targeting the pseudoknot site upstream of ORF1b were found to be the most effective in suppressing SARS-CoV-2 propagation. Pseudoknot-targeting Cas13b reduced expression of the spike protein and attenuated viral replication by 99%. It also inhibited the replication of multiple SARS-CoV-2 variants, exhibiting broad potency. We validated the therapeutic efficacy of this system in SARS-CoV-2-infected hACE2 transgenic mice, demonstrating that crRNA treatment significantly reduced viral titers. Our findings suggest that the pseudoknot region is a strategic site for targeted genomic degradation of SARS-CoV-2. Hence, pseudoknot-targeting Cas13b could be a breakthrough therapy for overcoming infections by SARS-CoV-2 or other RNA viruses. | - |
dc.language | English | - |
dc.publisher | CELL PRESS | - |
dc.title | Pseudoknot-targeting Cas13b combats SARS- CoV-2 infection by suppressing viral replication | - |
dc.type | Article | - |
dc.identifier.wosid | 001020893100001 | - |
dc.identifier.scopusid | 2-s2.0-85151659491 | - |
dc.type.rims | ART | - |
dc.citation.volume | 31 | - |
dc.citation.issue | 6 | - |
dc.citation.beginningpage | 1675 | - |
dc.citation.endingpage | 1687 | - |
dc.citation.publicationname | MOLECULAR THERAPY | - |
dc.identifier.doi | 10.1016/j.ymthe.2023.03.018 | - |
dc.contributor.localauthor | Do Heo, Won | - |
dc.contributor.nonIdAuthor | Han, Hee-Jeong | - |
dc.contributor.nonIdAuthor | Lee, Gun-Hee | - |
dc.contributor.nonIdAuthor | Yang, Ju-Hee | - |
dc.contributor.nonIdAuthor | Song, Byeong-Min | - |
dc.contributor.nonIdAuthor | Tark, Dongseob | - |
dc.contributor.nonIdAuthor | Choi, Byeong-Sun | - |
dc.contributor.nonIdAuthor | Kang, Sang -Min | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | anti-SARS-CoV-2 drug | - |
dc.subject.keywordAuthor | mRNA-encoded CRISPR-Cas13 system | - |
dc.subject.keywordAuthor | pseudoknot region | - |
dc.subject.keywordAuthor | viral frameshifting site | - |
dc.subject.keywordPlus | NEUTRALIZING ANTIBODIES | - |
dc.subject.keywordPlus | SARS-COV-2 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.